Beam Therapeutics

Beam Therapeutics

Focus:

Type: Public Corporation
Founded: 2017


Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.

Leadership
David Liu
Founder (not involved anymore)
Past Roles
Founder (Editas Medicine)
Founder (Beam Therapeutics)
Founder (Prime Medicine)

Feng Zhang
Founder (not involved anymore)
Past Roles
Founder (Editas Medicine)
Founder (Beam Therapeutics)


Financial Performance



Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2018
83.6 / 83.6M USD
87M USD
Series A
2019
135.0 / 135.0M USD
135M USD
Series B
2020
180M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Venture Capital
United States
Venture Capital
United States
Private Equity
United States
Venture Capital
United Kingdom
Venture Capital
United States
Corporate Venture
United States
Venture Capital
United States
Venture Capital
United States
Venture Capital
United States
Private Equity
United States
*More data available at: [CB Insights] [CrunchBase] [PitchBook]

Related
News